Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN.NE)

Cybin Inc (CYBN.NE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 82,580
  • Shares Outstanding, K 176,560
  • Annual Sales, $ 0 K
  • Annual Income, $ -67,631 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.28
Trade CYBN.NE with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.33
  • Most Recent Earnings -0.06 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.460 +2.17%
on 12/02/22
0.670 -29.85%
on 11/07/22
-0.130 (-21.67%)
since 11/04/22
3-Month
0.460 +2.17%
on 12/02/22
1.470 -68.03%
on 09/06/22
-0.920 (-66.19%)
since 09/02/22
52-Week
0.460 +2.17%
on 12/02/22
1.820 -74.18%
on 12/06/21
-1.310 (-73.60%)
since 12/03/21

Most Recent Stories

More News
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Business Highlights

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept....

CYBN.NE : 0.470 (+1.08%)
CYBN : 0.3534 (-0.98%)
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced that the Company presented...

CYBN.NE : 0.470 (+1.08%)
CYBN : 0.3534 (-0.98%)
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today reported unaudited financial...

CYBN.NE : 0.470 (+1.08%)
CYBN : 0.3534 (-0.98%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END

CYBN.NE : 0.470 (+1.08%)
MRVL.VN : 0.140 (-3.45%)
SAGE : 43.52 (-0.21%)
NERV : 3.32 (-2.35%)
ATAI : 3.48 (-1.97%)
CYBN : 0.3534 (-0.98%)
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to announce that its...

CYBN.NE : 0.470 (+1.08%)
CYBN : 0.3534 (-0.98%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Schedule for Upcoming Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s...

CYBN.NE : 0.470 (+1.08%)
CYBN : 0.3534 (-0.98%)
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to announce its participation...

CYBN.NE : 0.470 (+1.08%)
CYBN : 0.3534 (-0.98%)
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced an upcoming presentation at...

CYBN.NE : 0.470 (+1.08%)
CYBN : 0.3534 (-0.98%)
Cybin (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its EMBARK Psychedelic-Assisted Psychotherapy Training Program have announced...

CYBN.NE : 0.470 (+1.08%)
CYBN : 0.3534 (-0.98%)
Cybin’s EMBARK Program Announces Graduation of Facilitators

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics ® ”, today announced the graduation...

CYBN.NE : 0.470 (+1.08%)
CYBN : 0.3534 (-0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.527
2nd Resistance Point 0.513
1st Resistance Point 0.492
Last Price 0.470
1st Support Level 0.457
2nd Support Level 0.443
3rd Support Level 0.422

See More

52-Week High 1.820
Fibonacci 61.8% 1.300
Fibonacci 50% 1.140
Fibonacci 38.2% 0.980
Last Price 0.470
52-Week Low 0.460

See More

Business Summary

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems,...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar